Tango Therapeutics, Inc. (TNGX), a clinical-stage precision oncology company, priced the public offering of 18.17 million shares at $30.00 per share and pre-funded warrants to purchase up to 1.833 million shares at $29.99 per pre-funded warrant.
The gross proceeds of the offering are approximately $600 million, upsized from the previously announced $500 million.
All of the shares and pre-funded warrants in the offering are to be sold by Tango, with closing expected on or about June 11, 2026.
Additionally, the company has granted underwriters a 30-day option to purchase up to 3.01 million shares at the offering price.
J.P. Morgan, Leerink Partners, Cantor and Stifel are acting as joint book-running managers for the offering.
Tango shares closed Tuesday at $31.56, up 2.04%. In the overnight market, the shares are trading at $31.14, down 1.33%.
For more such biotech stock news, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.